TELO news

Telomir Pharmaceuticals announced peer-reviewed research demonstrating Telomir-Zn's ability to improve visual function and restore retinal structure in an AMD model. The findings validate the company's epigenetic mechanism of action and suggest broader applications beyond cancer.

Telomir reported preclinical findings from The Ohio State University demonstrating Telomir-Zn inhibits cell growth in both human and canine osteosarcoma models, supporting parallel development pathways.

Telomir Pharmaceuticals announced peer-reviewed publication of preclinical data demonstrating that Telomir-Zn produced dose-dependent survival improvements and reduced hepatic copper burden in a Wilson's disease model. The findings support the drug candidate's biological activity and potential thera…